Trius Therapeutics

Organization Address
4747 Executive Dr, Ste 1100
San Diego, CA 92121-3114

Organization Phone
(858) 452-0370


Biotech and Pharmaceutical

Organization Description

Trius Therapeutics is an early-stage biopharmaceutical company developing antibiotics to treat life-threatening bacterial infections. Torezolid phosphate, its lead candidate, is an IV- and orally-administered antibiotic being studied for its potential to treat antibiotic-resistant strains of staph infection, known as MRSA (methicillin-resistant Staphylococcus aureus). The company will market torezolid phosphate to hospitals and other health care providers if and when it is approved by the FDA. Trius went public in 2010 through an IPO worth about $50 million. The company intends to use the money to further the development of torezolid phosphate and fund other clinical trials.